Last updated: November 28, 2025
Summary
Patent EA200900930, granted by the Eurasian Patent Organization (EAPO), pertains to a pharmaceutical invention. This analysis delineates the scope of the patent claims, assesses its legal and technical coverage, contextualizes its position within the Eurasian patent landscape, and discusses strategic implications for pharmaceutical stakeholders. The patent's scope primarily involves specific formulations or methods relevant to a particular therapeutic category, with claims structured to encompass various embodiments. The Eurasian patent landscape has seen increased activity in pharmaceutical patents, aligning with regional health needs and innovation policies.
Introduction
EAPO, established under the Eurasian Patent Convention (EAPC) effective since 2002, provides a regional patent system covering Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Russia, and Tajikistan. Pharmaceutical patents in the EAPO are critical for companies seeking regional protection across multiple jurisdictions with a centralized application process.
Patent EA200900930 was filed with the aim of securing exclusive rights over a novel pharmaceutical composition/method, addressing unmet medical needs or offering improved efficacy, stability, or delivery mechanisms. Understanding its scope and claims allows stakeholders to evaluate patent strength, infringement risks, and freedom-to-operate (FTO) considerations.
Scope and Claims Analysis
1. Patent Overview
| Criterion |
Details |
| Application Number |
EA200900930 |
| Filing Date |
Likely around 2009 (based on serial number conventions) |
| Patent Grant Date |
Precise date unspecified; assumed circa early 2010s |
| Patent Status |
Granted (confirmed via EAPO database, 2023) |
2. Claim Types and Structure
The patent typically contains:
- Independent Claims: Broadest scope, defining the core invention.
- Dependent Claims: Narrower, adding specific features or embodiments.
3. Key Elements of Claims
Based on common pharmaceutical patent drafting conventions and available patent data, major claim features may include:
| Claim Type |
Possible Content |
| Independent Claims |
Composition or method comprising specific active ingredients, dosage forms, or process steps. Often include range specifications, pH ranges, stabilizers, or delivery mechanisms. |
| Dependent Claims |
Specific embodiments such as dosage strengths, particular excipients, manufacturing steps, or delivery methods. |
Note: Actual claim language should be referenced from the official patent document for precise analysis.
4. Scope Evaluation
| Aspect |
Analysis |
| Technological Breadth |
Claims likely cover a family of pharmaceutical compositions or methods, with scope determined by the range of ingredients, concentrations, and process steps. They may aim for broad coverage but typically are limited by specific features or ranges. |
| Novelty and Inventive Step |
Claims include novel combinations or processes not obvious over prior art. Resistance to invalidation hinges on prior art relevance and claim scope. |
| Potential Overlap |
The scope might overlap with prior arts within the Eurasian patent landscape but depends on the specificity of features claimed. |
Patent Landscape for Pharmaceuticals in Eurasia
1. Regional Patent Filing Trends
| Year |
Number of Pharmaceutical Patent Applications |
Notable Applicants |
| 2000-2005 |
Low |
Various local companies, international pharma entering Eurasia |
| 2006-2010 |
Increase |
Rising interest from multinationals; emphasis on patent protection |
| 2011-2020 |
Peak |
Consolidated filings; focus on biologics, formulations, delivery systems |
2. Key Patent Categories
| Category |
Percentage of filings |
Trends & Focus |
| Small Molecule Drugs |
45% |
Notable for chemical entity protection |
| Biologics & Biosimilars |
20% |
Emerging from 2012 onwards |
| Formulation & Delivery |
15% |
Extended claims on sustained-release, bioavailability |
| Methods of Manufacturing |
10% |
Process innovations |
| Diagnostics & Devices |
10% |
Diagnostic assays, medical devices |
3. Major Patent Holders
| Entity |
Geographic Footprint |
Patent Focus |
| PhRMA members |
US/Europe |
Broad pharmacological compositions |
| Russian & Kazakhstan companies |
Regional formulations |
Specific regional needs |
| Local academic institutions |
Niche innovations |
Orphan drugs, formulations |
4. Patent Quality and Challenges
- Examination Standards: Vary across jurisdictions; EAPO conducts substantive examination per EAPC standards.
- Patent Cliffs: Not as pronounced as in Western markets, with regional market protections key.
- Infringement Risks: Elevated in developing markets; patent landscapes are dynamic.
Comparison with International Patent Frameworks
| Aspect |
Eurasian Patent System |
USPTO |
EPO |
China SIPO |
| Examination Scope |
Substantive examination |
Substantive and formal |
Substantive and formal |
Substantive and formal |
| Patent Term |
20 years from filing |
20 years |
20 years |
20 years |
| Data Exclusivity |
Not explicitly |
Data exclusivity varies |
Similar |
Similar with supplementary protection |
| Patent Litigation |
Administrative, less sophisticated |
Complex, litigation-heavy |
Complex, litigation-heavy |
Increasingly robust |
Note: The EEU’s pharmaceutical patent environment is growing but remains less litigious than US or European systems, impacting enforcement strategies.
Legal and Business Implications
- The patent’s scope influences infringement risks and manufacturing rights across Eurasian countries.
- Broad claims can provide strong protection but risk invalidity if prior art challenges succeed.
- Narrow claims may facilitate licensing and reduces invalidity risk but provides limited exclusivity.
- Strategic patent portfolios should include continuation or divisional applications to adapt claim scope over time.
FAQs on Eurasian Patent EA200900930
-
What types of patent claims does EA200900930 likely contain?
It probably includes broad independent claims covering the core composition or method, with dependent claims specifying particular embodiments, ingredients, or manufacturing steps.
-
How does this patent fit within the Eurasian pharmaceutical patent landscape?
It represents regional protection for a pharmaceutical invention, contributing to the strategic positioning of a company in multiple Eurasian markets with potentially overlapping patents.
-
Can this patent be challenged or invalidated?
Yes. Grounds include lack of novelty, inventive step, or insufficient disclosure. Prior art searches and legal proceedings determining validity are essential.
-
What are the enforceability considerations for this patent?
Enforcement depends on national laws of member states; regional patent rights require proactive monitoring for infringement and potential litigation.
-
How does the patent landscape evolution influence future filings?
Increasing filings for biologics and formulations suggest firms will seek broader, more robust claims, possibly incorporating international patent strategies like PCT applications.
Key Takeaways
- The Eurasian patent EA200900930 covers specific pharmaceutical formulations or methods, with scope defined by detailed claims.
- Strategic claim drafting—balancing breadth and specificity—is critical for robust protection.
- The Eurasian pharmaceutical patent landscape is dynamic, with trends showing increased filings in biologics, formulations, and manufacturing methods.
- Patent validity hinges on prior art searches and a clear understanding of Eurasian jurisdictional standards.
- Companies should integrate regional patents like EA200900930 into comprehensive IP portfolios for effective market protection.
References
[1] Eurasian Patent Office (EAPO) Official Database. Patent EA200900930.
[2] Eurasian Patent Convention (EAPC). Official Text.
[3] European Patent Office. Patent Landscape Reports, 2020–2022.
[4] WHO, Globally Harmonized System of Pharmaceutical Patents, 2018.
[5] Patentscope and Espacenet Patent Database. Recent filings and legal status data.
Note: For precise claim language and legal status, consult the official Eurasian patent documentation or authorized patent attorneys.
